Suzhou’s Innovent Bio will collaborate with Beijing Shenogen Pharma to test a combination of Innovent’s approved PD-1 drug, Tyvyt® with Shenogen’s SNG1005 in patients with advanced cancer. SNG1005 is a conjugate of angiopep-2 and paclitaxel that is designed to cross the blood-brain barrier. Shenogen has been approved to conduct a China Phase II/III trial of SNG1005 in patients with breast cancer carcinoma brain metastases (BCBS). In late 2018, Tyvyt® was approved in China to treat classical Hodgkin’s lymphoma. Innovent develops biologics for oncology, while Shenogen is a discovery/development pharma. Source: China Biotoday
